GH&B Cluster Lead (MEA + TUR)

Getting to know GH&B - Global Hospital & Biosimilars (GH&B) makes the products that are the foundation of hospital care — sterile injectables and biosimilars – that reach more than 100 million patients annually, generating $5 billion in revenue for Pfizer. These are not niche products; they are for when patients are at the most vulnerable, essential to access and acute care delivery worldwide. - GH&B is Pfizer's only truly end-to-end business, spanning from our 12 global manufacturing sites through to commercial in a single integrated organization. It was created to give this portfolio dedicated focus, clearer accountability, and a fit-for-purpose operating model — recognizing that GH&B's portfolio has different economics, customer dynamics, and execution needs than Pfizer's innovative business. - By bringing Commercial and Supply into one organization, GH&B enables faster decision-making, stronger prioritization, and expanded capabilities for this important portfolio. - Our ambition: Rebuild a healthy operation positioned to serve patients for generations to come Use Your Power for Purpose - The Cluster Lead holds full P&L accountability for the commercial business across various countries across the Middle East, North Africa, and Turkey — a diverse set of markets with varying scale and maturity within a predominantly mixed commercial environment combining public tenders, private market negotiations, and retail/out-of-pocket channels. Distinguished by a plant-to-patient perspective, the role spans the full commercial value chain, from portfolio and pricing strategy through tender and contracting execution to patient access, across biosimilars and generics (Oncology, Immunology/Inflammation). - This is a build-and-shape mandate and the perfect opportunity for entrepreneurial leaders: the Cluster Lead will stand up a new cluster operating model from the ground up, setting strategic direction across in-market and launch assets while